Mode
Text Size
Log in / Sign up

Immunoglobulin A Nephropathy

Part of Nephritis

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Immunoglobulin A Nephropathy

4 trials tracked for Immunoglobulin A Nephropathy.

4Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 3 Phase 1 1
  1. Phase 2 Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade Completed
  2. Phase 2 A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN Completed
  3. Phase 2 Safety and Efficacy Study of VIS649 for IgA Nephropathy Completed
  4. Phase 1 First in Human Study to Assess Safety of VIS649 in Healthy Subjects Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Nephritis

Related studies from across the Nephritis family.

Mechanism-based strategies including CAR-T and bispecific engagers offer options for rituximab-resistant primary membranous nephropathy
Allergy & Immunology Sys. Review
Mechanism-based strategies including CAR-T and bispecific engagers offer options for rituximab-resistant primary membranous nephropathy New Strategies Target Treatment Resistance in Membranous Nephropathy
This systematic review examines the multifactorial mechanisms of rituximab resistance in patients with primary membranous nephropathy. It id…
Researchers identify new ways to treat primary membranous nephropathy when standard rituximab treatments do not work.
Wiskott-Aldrich syndrome with IgA nephropathy requires early recognition and multidisciplinary management
Pediatrics Sys. Review
Wiskott-Aldrich syndrome with IgA nephropathy requires early recognition and multidisciplinary management Kidney and immune issues linked to rare blood disorders in a boy
This narrative review and case presentation describes a 10-year-old boy with Wiskott-Aldrich syndrome/X-linked thrombocytopenia and IgA neph…
A 10-year-old boy with rare blood disorders developed kidney disease, showing how these conditions can affect multiple organs.
Meta-Analysis Reveals Shared Genetic Loci in Pediatric Nephrotic Syndrome and IgA Nephropathy
Psychiatry Meta-analysis
Meta-Analysis Reveals Shared Genetic Loci in Pediatric Nephrotic Syndrome and IgA Nephropathy Genetic clues link immune cells to pediatric kidney disease risks
A meta-analysis of GWAS data identified nine genome-wide significant loci for pediatric steroid-sensitive nephrotic syndrome and 19 pleiotro…
A large genetic analysis connects specific immune cell pathways to pediatric kidney conditions, offering new targets for future treatments.
Rituximab rechallenge caused severe hypersensitivity reaction in a patient with membranous nephropathy
Drug Pipeline Sys. Review
Rituximab rechallenge caused severe hypersensitivity reaction in a patient with membranous nephropathy A third Rituximab dose caused severe shock in a man with kidney disease
This case report describes a 52-year-old male with biopsy-proven primary membranous nephropathy who received a third 1 g infusion of rituxim…
A man with kidney disease developed life-threatening shock after a third Rituximab infusion, highlighting the need for careful monitoring an…
Telitacicept reduces proteinuria in adults with IgA nephropathy in Phase 3 trial
Drug Pipeline RCT
Telitacicept reduces proteinuria in adults with IgA nephropathy in Phase 3 trial New Drug Slashes Kidney Damage Risk in IgA Nephropathy Patients
This is an interim analysis of a Phase 3, multicenter, randomized, placebo-controlled trial in 318 adults with IgA nephropathy and persisten…
A targeted therapy reduced protein in urine by 55 percent more than placebo in people with IgA nephropathy, offering new hope for slowing ki…
Scoping review finds SGLT2 inhibitors show kidney protection in IgA nephropathy
Rheumatology RCT
Scoping review finds SGLT2 inhibitors show kidney protection in IgA nephropathy Two major trials show kidney-protective effects for a specific IgA nephropathy group
This scoping review synthesizes evidence on SGLT2 inhibitors in IgA nephropathy.
Two large trials found kidney-protective effects for some IgA nephropathy patients taking SGLT2 inhibitors, while real-world data showed red…
Narrative review discusses potential therapeutic roles of herbal compounds in membranous nephropathy
Urology Sys. Review
Narrative review discusses potential therapeutic roles of herbal compounds in membranous nephropathy Ancient Herbs Could Protect Kidneys From Autoimmune Damage
This narrative review explores the potential therapeutic roles of specific herbal compounds, including icariin and astragaloside IV, for mem…
Scientists are finding new ways to use natural plant compounds to protect damaged kidney filters.
Dyslipidemia linked to poorer renal survival in primary IgA nephropathy patients
Nephrology Cohort
Dyslipidemia linked to poorer renal survival in primary IgA nephropathy patients High cholesterol linked to faster kidney failure in IgA nephropathy
This retrospective observational cohort study of 458 primary IgA nephropathy patients found that dyslipidemia was associated with poorer ren…
People with IgA nephropathy and high cholesterol face a higher risk of kidney failure, a new study finds.
Obinutuzumab-guided regimen achieves high remission in refractory membranous nephropathy patients
Dermatology Cohort
Obinutuzumab-guided regimen achieves high remission in refractory membranous nephropathy patients New Dosing Strategy Helps Kidney Disease Patients Who Didn’t Respond to Standard Treatment
This single-center retrospective cohort study evaluated 33 patients with refractory membranous nephropathy treated with a B-cell reconstitut…
For patients with a stubborn kidney disease who ran out of options, a smarter dosing strategy may offer a new path to recovery.
Rituximab pharmacokinetics vary widely in membranous nephropathy, minimal change disease, and lupus nephritis patients
Drug Pipeline Cohort
Rituximab pharmacokinetics vary widely in membranous nephropathy, minimal change disease, and lupus nephritis patients Rituximab Works — But Only If Your Body Keeps Enough of It
This review examined pharmacokinetic profiling of rituximab in patients with glomerular diseases.
Rituximab helps kidney disease patients only if their bodies keep enough of it in the blood, since some people clear the drug too fast and g…
Review of Traditional Chinese Botanical Medicine in Membranous Nephropathy
Drug Pipeline Meta-analysis
Review of Traditional Chinese Botanical Medicine in Membranous Nephropathy A review examines traditional Chinese medicine for kidney condition known as membranous nephropathy
This narrative review examines the use of Traditional Chinese Botanical Medicine (CHMs) and their active metabolites for membranous nephropa…
Traditional Chinese botanical medicines show promise for treating membranous nephropathy, but this review found no proof of their safety or …
Podocyte morphometrics correlate with albuminuria and eGFR decline in IgA nephropathy cohort
Nephrology Cohort
Podocyte morphometrics correlate with albuminuria and eGFR decline in IgA nephropathy cohort Tiny Footprints Predict Kidney Disease Progression
A single-center observational cohort of 37 patients with glomerulonephritis found that high-resolution podocyte morphometrics correlated wit…
Tiny changes in kidney cell shapes now predict disease progression better than standard tests, offering earlier warnings for patients with I…